| Screening Study for Participants With Malignant Tumors (NCT05419375) | Hoffmann-La Roche | 2022-07-22 |
| A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors (NCT06873542) | Heronova Pharmaceuticals | 2022-07-08 |
| Study of INCB123667 in Subjects With Advanced Solid Tumors (NCT05238922) | Incyte Corporation | 2022-07-05 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials (NCT05203172) | Pfizer | 2022-07-05 |
| A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. (NCT07016997) | Chiome Bioscience Inc. | 2022-06-27 |
| A Study of ZG005 in Patients With Advanced Solid Tumors (NCT06233292) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2022-06-17 |
| A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors (NCT05216965) | Mabwell (Shanghai) Bioscience Co., Ltd. | 2022-06-11 |
| S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (NCT05101070) | Shionogi | 2022-05-30 |
| Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors (NCT05740215) | Shandong New Time Pharmaceutical Co., LTD | 2022-05-23 |
| Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors (NCT05225584) | Kymera Therapeutics, Inc. | 2022-05-19 |
| A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (NCT05327946) | Boehringer Ingelheim | 2022-05-17 |
| A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors (NCT05387265) | CytomX Therapeutics | 2022-05-16 |
| Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors (NCT05231733) | SparX Biotech(Jiangsu) Co., Ltd. | 2022-05-01 |
| A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) (NCT05155332) | Boehringer Ingelheim | 2022-03-28 |
| A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (NCT05262400) | Pfizer | 2022-03-14 |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (NCT05315700) | ORIC Pharmaceuticals | 2022-03-10 |
| A Study of TAK-103 in Adult With Solid Tumors (NCT05164666) | Takeda | 2022-01-05 |
| HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study (NCT05167071) | Harbour BioMed (Guangzhou) Co. Ltd. | 2021-12-28 |
| Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (NCT04939701) | Astellas Pharma Global Development, Inc. | 2021-12-23 |
| A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors (NCT05149027) | Harbour BioMed (Guangzhou) Co. Ltd. | 2021-12-20 |
| Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors (NCT04261413) | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. | 2021-12-13 |
| Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (NCT05024214) | 3D Medicines (Sichuan) Co., Ltd. | 2021-11-15 |
| Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors (NCT05522582) | Yancheng First People's Hospital | 2021-11-15 |
| Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397) | Rain Oncology Inc | 2021-11-01 |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors (NCT04337177) | Valent Technologies, LLC | 2021-10-25 |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (NCT05059522) | Pfizer | 2021-09-29 |
| A Phase 1b Study of ZN-c3 in Chinese Subjects (NCT04972422) | Zentera Therapeutics HK Limited | 2021-07-15 |
| Microtransplantation for Advanced and Relapsed Solid Tumors (NCT04937842) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2021-06-01 |
| IBI188 Combination Therapy in Solid Tumors (NCT04861948) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-05-25 |
| A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy (NCT04570423) | Spectrum Pharmaceuticals, Inc | 2021-05-20 |
| A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors (NCT04857138) | Hoffmann-La Roche | 2021-05-18 |
| Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors (NCT04774952) | Revolution Medicines, Inc. | 2021-04-07 |
| A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (NCT04730843) | Elpiscience Biopharma, Ltd. | 2021-04-01 |
| Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab (NCT04727164) | Harbour BioMed (Guangzhou) Co. Ltd. | 2021-02-28 |
| A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors (NCT04704154) | Bayer | 2021-02-03 |
| To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 (NCT04674748) | Incyte Biosciences Japan GK | 2021-02-03 |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (NCT04589845) | Hoffmann-La Roche | 2021-01-18 |
| A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. (NCT04642365) | Hoffmann-La Roche | 2021-01-04 |
| A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors (NCT04672460) | Pfizer | 2020-12-21 |
| Mobile Sensor Technologies to Assess General Symptomology of People With Cancer (NCT04465214) | National Cancer Institute (NCI) | 2020-11-23 |
| A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors. (NCT04341259) | Hoffmann-La Roche | 2020-11-03 |
| Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain (NCT04442425) | National Cancer Institute (NCI) | 2020-10-27 |
| A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors (NCT04685226) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-09-27 |
| Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors (NCT04260009) | Takeda | 2020-09-01 |
| Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China (NCT03998345) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2020-07-25 |
| A Study of DF6002 Alone and in Combination With Nivolumab (NCT04423029) | Dragonfly Therapeutics | 2020-07-13 |
| A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (NCT04405778) | Takeda | 2020-07-10 |
| JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (NCT04418167) | JS InnoPharm, LLC | 2020-06-18 |
| A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer (NCT06636435) | Chiome Bioscience Inc. | 2020-06-01 |
| A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (NCT04303858) | Hoffmann-La Roche | 2020-05-04 |
| MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. (NCT05877651) | HRYZ Biotech Co. | 2020-04-21 |
| A Study of RC98 in Subjects With Advanced Malignant Solid Tumors (NCT04190823) | RemeGen Co., Ltd. | 2020-03-15 |
| An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT04250155) | Genentech, Inc. | 2020-03-09 |
| KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (NCT04237649) | Novartis Pharmaceuticals | 2020-02-20 |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors (NCT03934372) | Incyte Biosciences International Sàrl | 2020-01-29 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors (NCT04029688) | Hoffmann-La Roche | 2020-01-27 |
| A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body (NCT04187456) | AstraZeneca | 2019-12-27 |
| A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors (NCT04158583) | Hoffmann-La Roche | 2019-12-09 |
| Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) (NCT04123366) | Merck Sharp & Dohme LLC | 2019-11-18 |
| Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) (NCT04174716) | Idience Co., Ltd. | 2019-11-06 |
| A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin (NCT04118842) | AstraZeneca | 2019-10-17 |
| A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (NCT03954067) | Astellas Pharma Global Development, Inc. | 2019-09-03 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors (NCT03965845) | Calithera Biosciences, Inc | 2019-06-25 |
| A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies (NCT03926143) | Bayer | 2019-06-03 |
| Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors (NCT03709680) | Pfizer | 2019-05-24 |
| A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors (NCT03861403) | Leap Therapeutics, Inc. | 2019-05-20 |
| GEN1046 Safety Trial in Patients With Malignant Solid Tumors (NCT03917381) | Genmab | 2019-05-14 |
| A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors (NCT03946800) | MedImmune LLC | 2019-05-08 |
| Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A (NCT03950297) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2019-05-01 |
| Avelumab Program Rollover Study (NCT03815643) | EMD Serono Research & Development Institute, Inc. | 2019-03-22 |
| Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) (NCT03745989) | Merck Sharp & Dohme LLC | 2019-02-22 |
| Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors (NCT03832569) | Memorial Sloan Kettering Cancer Center | 2019-02-20 |
| Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors (NCT03813615) | Memorial Sloan Kettering Cancer Center | 2019-01-21 |
| A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (NCT03762447) | Incyte Corporation | 2018-12-10 |
| Study of CD133KDEL Toxin in the Treatment for Solid Tumors (NCT02845414) | Masonic Cancer Center, University of Minnesota | 2018-12-01 |
| Study of Avelumab-M3814 Combinations (NCT03724890) | EMD Serono Research & Development Institute, Inc. | 2018-11-27 |
| 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors (NCT03366116) | National Cancer Institute (NCI) | 2018-11-05 |
| Biomarkers for Prediction of Tumor Response to Radiotherapy (NCT03744819) | Chuangzhen Chen | 2018-10-29 |
| A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors (NCT03708328) | Hoffmann-La Roche | 2018-10-15 |
| Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors (NCT03634982) | Revolution Medicines, Inc. | 2018-09-28 |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (NCT03486873) | Merck Sharp & Dohme LLC | 2018-08-21 |
| Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials (NCT03477175) | Eisai Inc. | 2018-08-16 |
| Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy (NCT03616834) | Effector Therapeutics | 2018-07-25 |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML (NCT03690154) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2018-07-23 |
| A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (NCT03539484) | Hoffmann-La Roche | 2018-07-04 |
| A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors (NCT03503604) | SuZhou Stainwei Biotech Inc. | 2018-05-01 |
| Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) (NCT03473925) | Merck Sharp & Dohme LLC | 2018-04-10 |
| A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) (NCT03347123) | Incyte Corporation | 2018-03-21 |
| A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) (NCT03255070) | Ambrx, Inc. | 2018-03-20 |
| A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors (NCT03361228) | Incyte Corporation | 2018-03-01 |
| A Study of E7130 in Participants With Solid Tumors (NCT03444701) | Eisai Co., Ltd. | 2018-02-05 |
| Prospective Patient Registry for Radiation Oncology Techniques and Quality (NCT02368106) | University of Maryland, Baltimore | 2018-02-01 |
| A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors (NCT03386942) | Eisai Inc. | 2017-11-28 |
| A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors (NCT03362723) | Hoffmann-La Roche | 2017-11-27 |
| A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors (NCT03264066) | Hoffmann-La Roche | 2017-11-23 |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (NCT03314935) | Incyte Corporation | 2017-11-21 |
| AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies (NCT03313557) | AstraZeneca | 2017-10-27 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224) | Apollomics Inc. | 2017-09-27 |
| Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients (NCT03258151) | Cui Yimin | 2017-09-25 |
| M3541 in Combination With Radiotherapy in Solid Tumors (NCT03225105) | EMD Serono Research & Development Institute, Inc. | 2017-09-06 |